No Data
No Data
Express News | Protara Therapeutics Inc: In Tara-002, Favorable Safety & Tolerability Profile With No Grade 2 or Greater Treatment-Related Adverse Events
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?
Dow Falls 50 Points; Kroger Posts Downbeat Sales
Wall Street Set to Open Flat Thursday; Initial Jobless Claims Higher Than Expected
Protara Therapeutics Shares Soar on Positive Data for Bladder Cancer Treatment Trials
Protare Therapeutics Shares Are Trading Higher After the Company Announced Results From Its Ongoing Phase 2 TARA-002 Trial in Patients With NMIBC.